Edition:
India

Zoetis Inc (ZTS.N)

ZTS.N on New York Stock Exchange

65.94USD
20 Oct 2017
Change (% chg)

-- (--)
Prev Close
$65.94
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
603,736
52-wk High
$66.11
52-wk Low
$46.86

Chart for

About

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock)... (more)

Overall

Beta: 1.03
Market Cap(Mil.): $31,180.87
Shares Outstanding(Mil.): 489.11
Dividend: 0.10
Yield (%): 0.66

Financials

  Industry Sector
P/E (TTM): -- 30.44 16.24
EPS (TTM): -- -- --
ROI: -- 14.17 10.90
ROE: -- 15.52 14.09

BRIEF-Zoetis announces pricing of $1.25 bln of senior notes

* Zoetis Inc - ‍agreed to sell $1.25 billion of senior notes, consisting of $750 million aggregate principal amount of 3.000% senior notes due 2027​

06 Sep 2017

BRIEF-Immunovaccine announces achievement of milestones in collaboration with Zoetis to develop veterinary vaccines

* Immunovaccine announces achievement of milestones in collaboration with Zoetis to develop veterinary vaccines Source text for Eikon: Further company coverage:

31 Aug 2017

BRIEF-Anatara and Zoetis to negotiate terms of an international Detach commercial agreement

* Anatara and Zoetis to negotiate terms of an international Detach® commercial agreement Source text for Eikon: Further company coverage:

21 Aug 2017

BRIEF-Zoetis reports Q2 earnings per share $0.50

* Q2 earnings per share view $0.53 -- Thomson Reuters I/B/E/S

08 Aug 2017

BRIEF-High Court of Ireland approves acquisition of Nexvet by Zoetis Inc's unit

* High Court of Ireland has approved acquisition of Nexvet by Zoetis Inc through its unit Source text for Eikon: Further company coverage:

28 Jul 2017

BRIEF-Zoetis gets grant from Bill & Melinda Gates foundation to develop sustainable livestock production in sub-Saharan Africa

* Will receive $14.4 million grant from Bill & Melinda Gates foundation over next 3 years

08 May 2017

BRIEF-Zoetis Q1 adjusted earnings per share $0.53

* Q1 earnings per share view $0.48 -- Thomson Reuters I/B/E/S

04 May 2017

BRIEF-Zoetis gets European Commission marketing authorization for Cytopoint

* Zoetis receives european commission marketing authorization for Cytopoint® (lokivetmab) Source text for Eikon: Further company coverage:

27 Apr 2017

Competitors

  Price Chg
Merck & Co., Inc. (MRK.N) $63.88 --
Bayer AG (BAYGn.DE) €117.85 -0.10
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €84.35 +0.54
Eli Lilly and Co (LLY.N) $87.23 --

Earnings vs. Estimates